These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29662024)

  • 1. PKIDB: A Curated, Annotated and Updated Database of Protein Kinase Inhibitors in Clinical Trials.
    Carles F; Bourg S; Meyer C; Bonnet P
    Molecules; 2018 Apr; 23(4):. PubMed ID: 29662024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Data-Driven Assessment of Non-Kinase Targets of Inhibitors of the Human Kinome.
    Mobasher M; Vogt M; Xerxa E; Bajorath J
    Biomolecules; 2024 Feb; 14(3):. PubMed ID: 38540679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor.
    Tamir TY; Drewry DH; Wells C; Major MB; Axtman AD
    Sci Rep; 2020 Sep; 10(1):15826. PubMed ID: 32985588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Representation of older patients in the safety analysis of protein kinase inhibitor registration studies.
    van Kampen E; van Bussel MTJ; Oude Munnink TH; Touw DJ; Broekman KE
    J Geriatr Oncol; 2023 Nov; 14(8):101636. PubMed ID: 37806290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Advances in Pyrazole-based Protein Kinase Inhibitors as Emerging Therapeutic Targets.
    Cetin A
    Comb Chem High Throughput Screen; 2023 Nov; ():. PubMed ID: 37946345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinase inhibitor data set for systematic analysis of representative kinases across the human kinome.
    Laufkötter O; Laufer S; Bajorath J
    Data Brief; 2020 Oct; 32():106189. PubMed ID: 32904416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How many kinases are druggable? A review of our current understanding.
    Anderson B; Rosston P; Ong HW; Hossain MA; Davis-Gilbert ZW; Drewry DH
    Biochem J; 2023 Aug; 480(16):1331-1363. PubMed ID: 37642371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-property Relationships Reported for the New Drugs Approved in 2023.
    Choi K
    Mini Rev Med Chem; 2024 Apr; ():. PubMed ID: 38676492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KLSD: a kinase database focused on ligand similarity and diversity.
    Yuan Y; Tang X; Li H; Lang X; Li C; Song Y; Sun S; Yang Y; Zhou Z
    Front Pharmacol; 2024; 15():1400136. PubMed ID: 38957398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RLKdb: A comprehensively curated database of plant receptor-like kinase families.
    Yin Z; Liu J; Dou D
    Mol Plant; 2024 Apr; 17(4):513-515. PubMed ID: 38384129
    [No Abstract]   [Full Text] [Related]  

  • 11. Trends in kinase drug discovery: targets, indications and inhibitor design.
    Attwood MM; Fabbro D; Sokolov AV; Knapp S; Schiöth HB
    Nat Rev Drug Discov; 2021 Nov; 20(11):839-861. PubMed ID: 34354255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
    Roskoski R
    Pharmacol Res; 2021 Mar; 165():105422. PubMed ID: 33434619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of FDA-approved small molecule protein kinase inhibitors.
    Roskoski R
    Pharmacol Res; 2019 Jun; 144():19-50. PubMed ID: 30877063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An integrative epigenome-based strategy for unbiased functional profiling of clinical kinase inhibitors.
    Gualdrini F; Rizzieri S; Polletti S; Pileri F; Zhan Y; Cuomo A; Natoli G
    Mol Syst Biol; 2024 Jun; 20(6):626-650. PubMed ID: 38724853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment.
    Rahban M; Joushi S; Bashiri H; Saso L; Sheibani V
    Front Chem; 2023; 11():1325214. PubMed ID: 38264122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New anticancer therapeutics impact fungal pathobiology, infection dynamics, and outcome.
    Palmucci JR; Messina JA; Tenor JL; Perfect JR
    PLoS Pathog; 2023 Dec; 19(12):e1011845. PubMed ID: 38127685
    [No Abstract]   [Full Text] [Related]  

  • 18. How Ligands Interact with the Kinase Hinge.
    Zhao Z; Bourne PE
    ACS Med Chem Lett; 2023 Nov; 14(11):1503-1508. PubMed ID: 37974950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerating Alchemical Free Energy Prediction Using a Multistate Method: Application to Multiple Kinases.
    Champion C; Gall R; Ries B; Rieder SR; Barros EP; Riniker S
    J Chem Inf Model; 2023 Nov; 63(22):7133-7147. PubMed ID: 37948537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate Cancer Progression Relies on the Mitotic Kinase Citron Kinase.
    Rawat C; Ben-Salem S; Singh N; Chauhan G; Rabljenovic A; Vaghela V; Venkadakrishnan VB; Macdonald JD; Dahiya UR; Ghanem Y; Bachour S; Su Y; DePriest AD; Lee S; Muldong M; Kim HT; Kumari S; Valenzuela MM; Zhang D; Hu Q; Cortes Gomez E; Dehm SM; Zoubeidi A; Jamieson CAM; Nicolas M; McKenney J; Willard B; Klein EA; Magi-Galluzzi C; Stauffer SR; Liu S; Heemers HV
    Cancer Res; 2023 Dec; 83(24):4142-4160. PubMed ID: 37801613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.